Canopy Growth Corp vs Schwab US Large Cap Growth ETF — how do they compare? Canopy Growth Corp trades at $0.96 (market cap $398.46M), while Schwab US Large Cap Growth ETF trades at $34.84. The key difference: Schwab US Large Cap Growth ETF is trading nearer its 52-week high, Canopy Growth Corp nearer its low. Which is the better fit depends on your goals.
| CGC | SCHG | |
|---|---|---|
Market Cap | $398.46M | — |
Sector | Health | Sector/Thematic |
52-Week High | $1.92 | $35.30 |
52-Week Low | $0.86 | $28.10 |
Enterprise Value | $337.90M | — |
Signals from Pluang's Aura AI — not financial advice
Canopy Growth (CGC) trades at $0.96, down 1.15% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported a net loss of $598.12 million in 2025, with revenue declining to $269 million, though recent quarterly earnings showed one beat and two misses against expectations. Cash flow remains negative, but the balance sheet shows improving debt-to-asset ratios, down to 33.13% in 2025 from 53.61% in 2023.
The outlook is cautious; while cost-cutting and restructuring efforts are underway, profitability remains elusive, and the stock faces risks including potential delisting due to low share price. Analyst sentiment is divided, with 33% recommending buy, 41% hold, and 26% sell. Investors should weigh the potential for a turnaround against significant operational and regulatory challenges in the cannabis sector.
SCHG, the Schwab U.S. Large-Cap Growth ETF, trades at $34.37, down 0.81% on the day. The technical outlook is bullish with moving averages signaling strength, while oscillators are neutral. Recent news highlights its concentrated exposure to AI-driven tech giants like Nvidia, Apple, and Microsoft, positioning it for potential growth from AI capital expenditure trends. The fund's portfolio carries a P/E around 32x, reflecting premium valuations amid moderate 2026 performance.
Outlook: SCHG offers leveraged growth potential through top tech holdings but faces risks from high concentration and interest rate sensitivity. Upside hinges on AI adoption, while downside could stem from tech sector volatility or economic shifts. Institutional inflows suggest confidence, yet investors must weigh valuation against diversification limits.
Trailing returns across standard periods
Latest headlines on both assets
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →